ArticlemedRxiv : the preprint server for health sciences2026
Beyond severity: Mapping cognitive heterogeneity in schizophrenia at the structural level.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cognitive heterogeneity is a fundamental aspect of schizophrenia (SCZ), but conventional domain-specific score-based approaches reduce cognition to single values, overlooking its structure and primarily reflecting the severity of cognitive impairment rather than qualitative differences. To address this gap, this study derived and validated a normative latent cognitive structure (N-LCS) serve as a reference to evaluate whether individual cognition aligns with the norm, providing a basis for characterizing cognitive heterogeneity in SCZ. Three deviation metrics represent the deviation magnitude (CDM), the angular deviation (CDA), and the domain driving the deviation (CDD). CDM showed a linear increase from healthy controls (HC) to unaffected siblings (UC) and SCZ patients. CDA differed between HC and the other two groups, but not between UC and SCZ. Reasoning remained the most frequent CDD, whereas processing speed declined across the SCZ liability spectrum. These findings imply that heterogeneous changes in cognitive structure already emerge in the UC stage, preceding both clinical onset and measurable score-level differences. Cognitive heterogeneity in SCZ can be delineated by three deviation dimensions: 53.1% of patients had reasoning as the CDD, with moderate CDM and CDA, suggesting that their cognitive structure is preserved relative to the N-LCS, whereas 31.2% had processing speed as the CDD, with larger CDM and intermediate CDA, and higher HAMA scores. The N-LCS captures signal beyond conventional score-based measures, supporting its utility and informing individualized treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.